Piramal Phytocare Limited

532979

INE122J01015

End-of-day quote Bombay S.E. Other stock markets 06:00:00 2019-12-09 pm EST			5-day change	1st Jan Change
22.55 ^INR	-4.04%		-7.96%	-.--%

2019	Piramal Enterprises Limited completed the acquisition of remaining 82.5% in Piramal Phytocare Limited.	CI
2019	Piramal Phytocare Limited Announces Resignation of Ankit Kotak as Chief Financial Officer	CI

Piramal Phytocare Limited Appoints Ankit Kotak as Chief Investor Relations Officer

November 02, 2018 at 10:00 am EDT

Piramal Phytocare Limited announced that Mr. Ankit Kotak shall be the Chief Investor Relations Officer for the purpose of Code for Fair Disclosure of Information & Determination of Materiality.

Latest news about Piramal Phytocare Limited

Piramal Enterprises Limited completed the acquisition of remaining 82.5% in Piramal Phytocare Limited.	19-12-01	CI
Piramal Phytocare Limited Announces Resignation of Ankit Kotak as Chief Financial Officer	19-11-05	CI
Piramal Phytocare Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019	19-11-04	CI
Piramal Phytocare Limited Reports Earnings Results for the First Quarter Ended June 30, 2019	19-08-05	CI
Piramal Phytocare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	19-05-07	CI
Piramal Phytocare Limited Reports Earnings Results for the Third Quarter Ended December 31, 2018	19-02-05	CI
Piramal Phytocare Limited Appoints Ankit Kotak as Chief Investor Relations Officer	18-11-02	CI
Piramal Phytocare Limited Reports Earnings Results for the Second Quarter Ended September 30, 2018	18-11-02	CI
Piramal Phytocare Limited Announces Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2018	18-08-02	CI
Piramal Phytocare Limited Announces Chief Financial Officer Changes	18-05-28	CI
Piramal Phytocare Limited Reports Standalone Audited Earnings Results for the Fourth Quarter and Year Ended March 31, 2018	18-05-28	CI
Piramal Enterprises Limited agreed to acquire remaining 82.5% in Piramal Phytocare Limited for approximately INR 740 million.	18-05-27	CI
Piramal Phytocare Limited Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017	18-01-31	CI
Piramal Phytocare Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2017	17-11-07	CI
Piramal Phytocare Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2017	17-07-28	CI
Piramal Phytocare Limited Reports Standalone Audited Earnings Results for Fourth Quarter and Full Year Ended March 31, 2017	17-05-24	CI
Piramal Phytocare Limited Announces Audited Earnings Results for the Year Ended March 31, 2017	17-05-08	CI
Piramal Phytocare Enters into Agreements with Piramal Enterprises	17-04-12	CI
Piramal Phytocare Limited Announces Unaudited Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2017	17-04-12	CI
Piramal Phytocare Limited Appoints Rashida Najmi as Non - Executive Director of the Company	17-04-12	CI
Piramal Phytocare Limited Announces Resignation of Vandana Sonavaria as Director	17-02-21	CI
Piramal Phytocare Limited Announces Unaudited Standalone Financial Results for the Third Quarter and Nine Months Ended December 31, 2016	17-02-08	CI
Piramal Phytocare Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2016	16-10-25	CI
Piramal Life Sciences Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2016	16-08-05	CI
Piramal Phytocare Limited Announces Unaudited Standalone Earnings Results for the Fourth Quarter and Audited Standalone Earnings Results for the Full Year Ended March 31, 2016	16-05-14	CI

Chart Piramal Phytocare Limited

Duration

Period

More charts

Piramal Phytocare Limited, formerly Piramal Life Sciences Limited, is engaged in pharmaceutical business. The Company is engaged in the manufacturing and marketing of herbal products and other products. Its medicinal products are made from herbal extracts. It is engaged in global marketing of finished pharmaceutical dosage forms especially Proprietary Formulations, wherein the active ingredients are derived from natural sources. It offers a range of products that are developed to manage lifestyle ailments, such as diabetes, arthritis, obesity, constipation, liver damage, anxiety, sexual dysfunction, cough and cold. Its products include Sleecap capsule, Pylee capsule, Soyaklin forte capsule, Prementrid capsule, Zayata capsule, Rtunorm capsule, Khasceeze syrup, Intelimax capsule, Contudol gel, Phyleclip capsule, Contudol capsule, Sugarcare capsule, Stresscare capsule, Cardiocare capsule, Dormocare capsule, Femincare capsule and Menacare capsule. It is a part of the Piramal Group.

Sector

More about the company